Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
39
BSEM Quote, Financials, Valuation and Earnings
Last price:
$5.8000
Seasonality move
:
160.26%
Day range:
$5.5700 - $5.8900
52-week range:
$3.0932 - $15.7400
Dividend yield:
0%
P/E ratio:
6.81x
P/S ratio:
0.55x
P/B ratio:
1.94x
Volume:
29.1K
Avg. volume:
165.2K
1-year change:
-62.26%
Market cap:
$97.2M
Revenue:
$301.8M
EPS (TTM):
$0.85
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BSEM
BioStem Technologies, Inc.
|
$55.2M | $0.02 | -37.86% | -100% | $25.5000 |
|
GBLX
GB Sciences, Inc.
|
-- | -- | -- | -- | -- |
|
IOVA
Iovance Biotherapeutics, Inc.
|
$81M | -$0.18 | 66.62% | -58.03% | $9.11 |
|
PKTX
Protokinetix, Inc.
|
-- | -- | -- | -- | -- |
|
PSTV
Plus Therapeutics, Inc.
|
$1.2M | -$0.04 | 22.78% | -97.49% | $5.50 |
|
TVTX
Travere Therapeutics, Inc.
|
$147.7M | $0.37 | 64.27% | -87.94% | $42.3571 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BSEM
BioStem Technologies, Inc.
|
$5.8000 | $25.5000 | $97.2M | 6.81x | $0.00 | 0% | 0.55x |
|
GBLX
GB Sciences, Inc.
|
$0.0003 | -- | $122.1K | -- | $0.00 | 0% | 1.26x |
|
IOVA
Iovance Biotherapeutics, Inc.
|
$2.57 | $9.11 | $1B | -- | $0.00 | 0% | 3.40x |
|
PKTX
Protokinetix, Inc.
|
$0.0083 | -- | $3.3M | 23.85x | $0.00 | 0% | -- |
|
PSTV
Plus Therapeutics, Inc.
|
$0.26 | $5.50 | $35.3M | -- | $0.00 | 0% | 4.12x |
|
TVTX
Travere Therapeutics, Inc.
|
$30.6000 | $42.3571 | $2.7B | -- | $0.00 | 0% | 6.37x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BSEM
BioStem Technologies, Inc.
|
6.34% | 0.058 | 4.31% | 3.87x |
|
GBLX
GB Sciences, Inc.
|
-- | 6.983 | -- | -- |
|
IOVA
Iovance Biotherapeutics, Inc.
|
6.96% | -0.707 | 6.28% | 2.92x |
|
PKTX
Protokinetix, Inc.
|
-- | -0.614 | -- | 0.00x |
|
PSTV
Plus Therapeutics, Inc.
|
0.41% | -1.387 | 0.02% | 1.22x |
|
TVTX
Travere Therapeutics, Inc.
|
81.76% | 0.541 | 15.42% | 2.50x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BSEM
BioStem Technologies, Inc.
|
$9.2M | $1.4M | 44.01% | 48.25% | 13.83% | -- |
|
GBLX
GB Sciences, Inc.
|
-- | -$157.8K | -- | -- | -- | -$107.7K |
|
IOVA
Iovance Biotherapeutics, Inc.
|
$20M | -$89.8M | -50.35% | -54.43% | -133.06% | -$89.5M |
|
PKTX
Protokinetix, Inc.
|
-$12.6K | -$84.9K | -111.59% | -111.59% | -- | -$9.5K |
|
PSTV
Plus Therapeutics, Inc.
|
$1.3M | -$4.5M | -- | -- | -320.83% | -$2.6M |
|
TVTX
Travere Therapeutics, Inc.
|
$147.5M | $24.9M | -21.07% | -263.9% | 15.12% | -$871K |
BioStem Technologies, Inc. vs. Competitors
-
Which has Higher Returns BSEM or GBLX?
GB Sciences, Inc. has a net margin of 7.27% compared to BioStem Technologies, Inc.'s net margin of --. BioStem Technologies, Inc.'s return on equity of 48.25% beat GB Sciences, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BSEMBioStem Technologies, Inc.87.95% $0.03 $53.4M GBLXGB Sciences, Inc.-- -$0.00 -- -
What do Analysts Say About BSEM or GBLX?
BioStem Technologies, Inc. has a consensus price target of $25.5000, signalling upside risk potential of 339.66%. On the other hand GB Sciences, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that BioStem Technologies, Inc. has higher upside potential than GB Sciences, Inc., analysts believe BioStem Technologies, Inc. is more attractive than GB Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BSEMBioStem Technologies, Inc.0 0 0 GBLXGB Sciences, Inc.0 0 0 -
Is BSEM or GBLX More Risky?
BioStem Technologies, Inc. has a beta of -0.090, which suggesting that the stock is 108.955% less volatile than S&P 500. In comparison GB Sciences, Inc. has a beta of 11.330, suggesting its more volatile than the S&P 500 by 1032.978%.
-
Which is a Better Dividend Stock BSEM or GBLX?
BioStem Technologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GB Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioStem Technologies, Inc. pays -- of its earnings as a dividend. GB Sciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BSEM or GBLX?
BioStem Technologies, Inc. quarterly revenues are $10.5M, which are larger than GB Sciences, Inc. quarterly revenues of --. BioStem Technologies, Inc.'s net income of $761.1K is higher than GB Sciences, Inc.'s net income of -$190.5K. Notably, BioStem Technologies, Inc.'s price-to-earnings ratio is 6.81x while GB Sciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioStem Technologies, Inc. is 0.55x versus 1.26x for GB Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BSEMBioStem Technologies, Inc.0.55x 6.81x $10.5M $761.1K GBLXGB Sciences, Inc.1.26x -- -- -$190.5K
-
Which has Higher Returns BSEM or IOVA?
Iovance Biotherapeutics, Inc. has a net margin of 7.27% compared to BioStem Technologies, Inc.'s net margin of -135.28%. BioStem Technologies, Inc.'s return on equity of 48.25% beat Iovance Biotherapeutics, Inc.'s return on equity of -54.43%.
Company Gross Margin Earnings Per Share Invested Capital BSEMBioStem Technologies, Inc.87.95% $0.03 $53.4M IOVAIovance Biotherapeutics, Inc.29.61% -$0.25 $754.8M -
What do Analysts Say About BSEM or IOVA?
BioStem Technologies, Inc. has a consensus price target of $25.5000, signalling upside risk potential of 339.66%. On the other hand Iovance Biotherapeutics, Inc. has an analysts' consensus of $9.11 which suggests that it could grow by 254.52%. Given that BioStem Technologies, Inc. has higher upside potential than Iovance Biotherapeutics, Inc., analysts believe BioStem Technologies, Inc. is more attractive than Iovance Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BSEMBioStem Technologies, Inc.0 0 0 IOVAIovance Biotherapeutics, Inc.6 4 0 -
Is BSEM or IOVA More Risky?
BioStem Technologies, Inc. has a beta of -0.090, which suggesting that the stock is 108.955% less volatile than S&P 500. In comparison Iovance Biotherapeutics, Inc. has a beta of 0.765, suggesting its less volatile than the S&P 500 by 23.531%.
-
Which is a Better Dividend Stock BSEM or IOVA?
BioStem Technologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iovance Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioStem Technologies, Inc. pays -- of its earnings as a dividend. Iovance Biotherapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BSEM or IOVA?
BioStem Technologies, Inc. quarterly revenues are $10.5M, which are smaller than Iovance Biotherapeutics, Inc. quarterly revenues of $67.5M. BioStem Technologies, Inc.'s net income of $761.1K is higher than Iovance Biotherapeutics, Inc.'s net income of -$91.3M. Notably, BioStem Technologies, Inc.'s price-to-earnings ratio is 6.81x while Iovance Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioStem Technologies, Inc. is 0.55x versus 3.40x for Iovance Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BSEMBioStem Technologies, Inc.0.55x 6.81x $10.5M $761.1K IOVAIovance Biotherapeutics, Inc.3.40x -- $67.5M -$91.3M
-
Which has Higher Returns BSEM or PKTX?
Protokinetix, Inc. has a net margin of 7.27% compared to BioStem Technologies, Inc.'s net margin of --. BioStem Technologies, Inc.'s return on equity of 48.25% beat Protokinetix, Inc.'s return on equity of -111.59%.
Company Gross Margin Earnings Per Share Invested Capital BSEMBioStem Technologies, Inc.87.95% $0.03 $53.4M PKTXProtokinetix, Inc.-- -$0.00 $250.4K -
What do Analysts Say About BSEM or PKTX?
BioStem Technologies, Inc. has a consensus price target of $25.5000, signalling upside risk potential of 339.66%. On the other hand Protokinetix, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that BioStem Technologies, Inc. has higher upside potential than Protokinetix, Inc., analysts believe BioStem Technologies, Inc. is more attractive than Protokinetix, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BSEMBioStem Technologies, Inc.0 0 0 PKTXProtokinetix, Inc.0 0 0 -
Is BSEM or PKTX More Risky?
BioStem Technologies, Inc. has a beta of -0.090, which suggesting that the stock is 108.955% less volatile than S&P 500. In comparison Protokinetix, Inc. has a beta of 0.614, suggesting its less volatile than the S&P 500 by 38.569%.
-
Which is a Better Dividend Stock BSEM or PKTX?
BioStem Technologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protokinetix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioStem Technologies, Inc. pays -- of its earnings as a dividend. Protokinetix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BSEM or PKTX?
BioStem Technologies, Inc. quarterly revenues are $10.5M, which are larger than Protokinetix, Inc. quarterly revenues of --. BioStem Technologies, Inc.'s net income of $761.1K is higher than Protokinetix, Inc.'s net income of -$84.9K. Notably, BioStem Technologies, Inc.'s price-to-earnings ratio is 6.81x while Protokinetix, Inc.'s PE ratio is 23.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioStem Technologies, Inc. is 0.55x versus -- for Protokinetix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BSEMBioStem Technologies, Inc.0.55x 6.81x $10.5M $761.1K PKTXProtokinetix, Inc.-- 23.85x -- -$84.9K
-
Which has Higher Returns BSEM or PSTV?
Plus Therapeutics, Inc. has a net margin of 7.27% compared to BioStem Technologies, Inc.'s net margin of -316.61%. BioStem Technologies, Inc.'s return on equity of 48.25% beat Plus Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BSEMBioStem Technologies, Inc.87.95% $0.03 $53.4M PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M -
What do Analysts Say About BSEM or PSTV?
BioStem Technologies, Inc. has a consensus price target of $25.5000, signalling upside risk potential of 339.66%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 2040.08%. Given that Plus Therapeutics, Inc. has higher upside potential than BioStem Technologies, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than BioStem Technologies, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BSEMBioStem Technologies, Inc.0 0 0 PSTVPlus Therapeutics, Inc.4 0 0 -
Is BSEM or PSTV More Risky?
BioStem Technologies, Inc. has a beta of -0.090, which suggesting that the stock is 108.955% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.
-
Which is a Better Dividend Stock BSEM or PSTV?
BioStem Technologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioStem Technologies, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BSEM or PSTV?
BioStem Technologies, Inc. quarterly revenues are $10.5M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. BioStem Technologies, Inc.'s net income of $761.1K is higher than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, BioStem Technologies, Inc.'s price-to-earnings ratio is 6.81x while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioStem Technologies, Inc. is 0.55x versus 4.12x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BSEMBioStem Technologies, Inc.0.55x 6.81x $10.5M $761.1K PSTVPlus Therapeutics, Inc.4.12x -- $1.4M -$4.4M
-
Which has Higher Returns BSEM or TVTX?
Travere Therapeutics, Inc. has a net margin of 7.27% compared to BioStem Technologies, Inc.'s net margin of 15.59%. BioStem Technologies, Inc.'s return on equity of 48.25% beat Travere Therapeutics, Inc.'s return on equity of -263.9%.
Company Gross Margin Earnings Per Share Invested Capital BSEMBioStem Technologies, Inc.87.95% $0.03 $53.4M TVTXTravere Therapeutics, Inc.89.46% $0.25 $403.3M -
What do Analysts Say About BSEM or TVTX?
BioStem Technologies, Inc. has a consensus price target of $25.5000, signalling upside risk potential of 339.66%. On the other hand Travere Therapeutics, Inc. has an analysts' consensus of $42.3571 which suggests that it could grow by 38.42%. Given that BioStem Technologies, Inc. has higher upside potential than Travere Therapeutics, Inc., analysts believe BioStem Technologies, Inc. is more attractive than Travere Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BSEMBioStem Technologies, Inc.0 0 0 TVTXTravere Therapeutics, Inc.12 2 0 -
Is BSEM or TVTX More Risky?
BioStem Technologies, Inc. has a beta of -0.090, which suggesting that the stock is 108.955% less volatile than S&P 500. In comparison Travere Therapeutics, Inc. has a beta of 0.827, suggesting its less volatile than the S&P 500 by 17.33%.
-
Which is a Better Dividend Stock BSEM or TVTX?
BioStem Technologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Travere Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioStem Technologies, Inc. pays -- of its earnings as a dividend. Travere Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BSEM or TVTX?
BioStem Technologies, Inc. quarterly revenues are $10.5M, which are smaller than Travere Therapeutics, Inc. quarterly revenues of $164.9M. BioStem Technologies, Inc.'s net income of $761.1K is lower than Travere Therapeutics, Inc.'s net income of $25.7M. Notably, BioStem Technologies, Inc.'s price-to-earnings ratio is 6.81x while Travere Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioStem Technologies, Inc. is 0.55x versus 6.37x for Travere Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BSEMBioStem Technologies, Inc.0.55x 6.81x $10.5M $761.1K TVTXTravere Therapeutics, Inc.6.37x -- $164.9M $25.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 64x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
77
CPS alert for Feb 14
Cooper-Standard Holdings, Inc. [CPS] is up 32.06% over the past day.
Buy
91
SPHR alert for Feb 14
Sphere Entertainment Co. [SPHR] is down 0.2% over the past day.
Sell
39
IRON alert for Feb 14
Disc Medicine, Inc. [IRON] is down 21.88% over the past day.
